Real-World check: does aflibercept 8 mg hold up outside the lab?
NCT ID NCT06075147
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This observational study will follow 2,500 adults with vision loss from nAMD or DME who are already prescribed aflibercept 8 mg by their doctors. Researchers will collect data from routine visits over up to 24 months to see how vision changes. The goal is to understand how well the drug works in real-world settings, not in a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aflibercept 8 mg (eye injection)
What this could lead to
If successful, this study will provide real-world evidence on how well aflibercept 8 mg works for vision loss due to nAMD and DME, supporting its use in routine care.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new treatment but gathers data on an already approved drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VISUAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Multiple Locations, Australia
-
Many Locations
Multiple Locations, Canada
-
Many Locations
Multiple Locations, Denmark
-
Many Locations
Multiple Locations, Finland
-
Many Locations
Multiple Locations, France
-
Many Locations
Multiple Locations, Germany
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Japan
-
Many Locations
Multiple Locations, Netherlands
-
Many Locations
Multiple Locations, Norway
-
Many Locations
Multiple Locations, Portugal
-
Many Locations
Multiple Locations, Saudi Arabia
-
Many Locations
Multiple Locations, South Korea
-
Many Locations
Multiple Locations, Spain
-
Many Locations
Multiple Locations, Sweden
-
Many Locations
Multiple Locations, Switzerland
-
Many Locations
Multiple Locations, United Arab Emirates
-
Many Locations
Multiple Locations, United Kingdom